These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 22469813)

  • 1. RNA interference targeting CHFR enhances taxol chemosensitivity in endometrial cancer cells.
    Li X; Wang X; Yang Y; Xu C; Shen H
    Oncol Rep; 2012 Jul; 28(1):248-54. PubMed ID: 22469813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.
    Wang X; Yang Y; Xu C; Xiao L; Shen H; Zhang X; Li T; Li X
    Int J Gynecol Cancer; 2011 Aug; 21(6):996-1003. PubMed ID: 21792009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
    Satoh A; Toyota M; Itoh F; Sasaki Y; Suzuki H; Ogi K; Kikuchi T; Mita H; Yamashita T; Kojima T; Kusano M; Fujita M; Hosokawa M; Endo T; Tokino T; Imai K
    Cancer Res; 2003 Dec; 63(24):8606-13. PubMed ID: 14695171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CHFR mitotic checkpoint protein delays cell cycle progression by excluding Cyclin B1 from the nucleus.
    Summers MK; Bothos J; Halazonetis TD
    Oncogene; 2005 Apr; 24(16):2589-98. PubMed ID: 15674323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors.
    Ogi K; Toyota M; Mita H; Satoh A; Kashima L; Sasaki Y; Suzuki H; Akino K; Nishikawa N; Noguchi M; Shinomura Y; Imai K; Hiratsuka H; Tokino T
    Cancer Biol Ther; 2005 Jul; 4(7):773-80. PubMed ID: 16123600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1.
    Dong XL; Xu PF; Miao C; Fu ZY; Li QP; Tang PY; Wang T
    Biomed Pharmacother; 2012 Feb; 66(1):70-5. PubMed ID: 22264882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
    Yanokura M; Banno K; Kawaguchi M; Hirao N; Hirasawa A; Susumu N; Tsukazaki K; Aoki D
    Oncol Rep; 2007 Jan; 17(1):41-8. PubMed ID: 17143476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHFR-associated early G2/M checkpoint defects in breast cancer cells.
    Erson AE; Petty EM
    Mol Carcinog; 2004 Jan; 39(1):26-33. PubMed ID: 14694445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappaB.
    Kashima L; Toyota M; Mita H; Suzuki H; Idogawa M; Ogi K; Sasaki Y; Tokino T
    Oncogene; 2009 Jul; 28(29):2643-53. PubMed ID: 19448676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity.
    Chaturvedi P; Sudakin V; Bobiak ML; Fisher PW; Mattern MR; Jablonski SA; Hurle MR; Zhu Y; Yen TJ; Zhou BB
    Cancer Res; 2002 Mar; 62(6):1797-801. PubMed ID: 11912157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways.
    Li Z; Min W; Gou J
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1001-11. PubMed ID: 24036847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
    Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
    Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines.
    Whang YM; Park KH; Jung HY; Jo UH; Kim YH
    Cancer; 2009 Mar; 115(6):1253-66. PubMed ID: 19156899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic inactivation of CHFR in human tumors.
    Toyota M; Sasaki Y; Satoh A; Ogi K; Kikuchi T; Suzuki H; Mita H; Tanaka N; Itoh F; Issa JP; Jair KW; Schuebel KE; Imai K; Tokino T
    Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7818-23. PubMed ID: 12810945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR.
    Shtivelman E
    Mol Cancer Res; 2003 Nov; 1(13):959-69. PubMed ID: 14638868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation.
    Cheung HW; Ching YP; Nicholls JM; Ling MT; Wong YC; Hui N; Cheung A; Tsao SW; Wang Q; Yeun PW; Lo KW; Jin DY; Wang X
    Mol Carcinog; 2005 Aug; 43(4):237-45. PubMed ID: 15937956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of survivin by retinoic acid and its role in paclitaxel-mediated cytotoxicity in MCF-7 breast cancer cells.
    Pratt MA; Niu MY; Renart LI
    Apoptosis; 2006 Apr; 11(4):589-605. PubMed ID: 16528475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
    Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
    Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of modulators of protein kinases on taxol-induced apoptosis of human leukemic cells possessing disparate levels of p26BCL-2 protein.
    Ponnathpur V; Ibrado AM; Reed JC; Ray S; Huang Y; Self S; Bullock G; Nawabi A; Bhalla K
    Clin Cancer Res; 1995 Nov; 1(11):1399-406. PubMed ID: 9815937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo.
    Yuan J; Krämer A; Matthess Y; Yan R; Spänkuch B; Gätje R; Knecht R; Kaufmann M; Strebhardt K
    Oncogene; 2006 Mar; 25(12):1753-62. PubMed ID: 16278675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.